

CARACO PHARMACEUTICAL LABORATORIES LTD  
Form S-8 POS  
June 16, 2011

As filed with the Securities and Exchange Commission on June 16, 2011

Registration No. 33-82802

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

POST-EFFECTIVE AMENDMENT NO. 1 TO  
FORM S-8  
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

---

CARACO PHARMACEUTICAL LABORATORIES, LTD.  
(Exact name of registrant as specified in its charter)

Michigan  
(State or other jurisdiction of incorporation or  
organization)

38-2505723  
(I.R.S. Employer Identification No.)

1150 Elijah McCoy Drive  
Detroit, Michigan 48202  
Telephone: (313) 871-8400

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

---

1993 Stock Option Plan

---

(Full title of the plans)

GP. Singh, Chief Executive Officer  
1150 Elijah McCoy Drive  
Detroit, Michigan 48202  
Telephone: (313) 871-8400

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form S-8 POS

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company)

Smaller reporting company

---

---

---

DEREGISTRATION OF SECURITIES

Caraco Pharmaceutical Laboratories, Ltd. (“Caraco”) is filing this Post-Effective Amendment No. 1 to deregister unsold shares of common stock of Caraco that were registered under the Registration Statement on Form S-8 originally filed on approximately August 15, 1994 (Registration No. 33-82802) (the “Registration Statement”) for issuance pursuant to the Stock Option Plan, as amended (the “Plan”). The Registration Statement registered a total of 350,000 shares issuable pursuant to the Plan.

On June 14, 2011, Caraco completed its merger (the “Merger”) with Sun Laboratories, Inc., a Michigan corporation, pursuant to an Agreement and Plan of Merger, dated as of February 21, 2011. In connection with the Merger, Caraco hereby removes from registration the securities of Caraco registered but unsold under the Registration Statement.

---

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Detroit, State of Michigan on June 14, 2011.

CARACO PHARMACEUTICAL LABORATORIES,  
LTD.

By: GP. Singh  
GP. Singh  
Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons, in the capacities indicated, on June 14, 2011.

Name and Signature	Title
/s/ GP. Singh GP. Singh	Chief Executive Officer, Director (Principal Executive Officer)
/s/ Mukul Rathi Mukul Rathi	Interim Chief Financial Officer (Principal Financial and Accounting Officer)
/s/ Harin Mehta Harin Mehta	Director
/s/ Jayesh M. Shah Jayesh M. Shah	Director
Dilip S. Shanghvi	Director
Sudhir Valia	Director

---